Coya Therapeutics, Inc. Net Income
Coya Therapeutics, Inc. (COYA) reported Net Income of -$6.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-11
- Coya Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$6.64M.
- Coya Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$7.21M.
- Coya Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$5.71M.
- Coya Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$2.12M.
- Coya Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2025 was -$21.23M.
- Coya Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2024 was -$14.88M.
- Coya Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2023 was -$7.99M.
- Coya Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$12.24M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.64M 10-Q · filed 2026-08-11 | -$13.85M 10-Q · filed 2026-08-11 | -$19.55M derived: sum of 3 quarters · filed 2026-08-11 | -$21.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$7.21M 10-Q · filed 2026-08-11 | -$12.92M derived: sum of 2 quarters · filed 2026-08-11 | -$15.03M derived: sum of 3 quarters · filed 2026-08-11 | -$21.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$7.82M derived: sum of 2 quarters · filed 2026-03-16 | -$13.92M derived: sum of 3 quarters · filed 2026-08-11 | -$21.23M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$2.12M 10-Q · filed 2025-11-12 | -$8.21M derived: sum of 2 quarters · filed 2026-08-11 | -$15.52M 10-Q · filed 2025-11-12 | -$18.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$6.09M 10-Q · filed 2026-08-11 | -$13.40M 10-Q · filed 2026-08-11 | -$16.32M derived: sum of 3 quarters · filed 2026-08-11 | -$20.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$7.31M 10-Q · filed 2026-08-11 | -$10.22M derived: sum of 2 quarters · filed 2026-08-11 | -$14.24M derived: sum of 3 quarters · filed 2026-08-11 | -$17.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2024-12-31 | -$2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$6.94M derived: sum of 2 quarters · filed 2026-03-16 | -$9.83M derived: sum of 3 quarters · filed 2026-03-16 | -$14.88M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$4.02M 10-Q · filed 2025-11-12 | -$6.91M derived: sum of 2 quarters · filed 2025-11-12 | -$11.97M 10-Q · filed 2025-11-12 | -$10.70M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$2.89M 10-Q · filed 2025-11-12 | -$7.94M 10-Q · filed 2025-08-12 | -$6.68M derived: sum of 3 quarters · filed 2025-11-12 | -$10.10M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | -$5.05M 10-Q · filed 2025-11-12 | -$3.79M derived: sum of 2 quarters · filed 2025-11-12 | -$7.21M derived: sum of 3 quarters · filed 2025-11-12 | -$10.30M derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$2.16M derived: sum of 2 quarters · filed 2025-03-18 | -$5.25M derived: sum of 3 quarters · filed 2025-03-18 | -$7.99M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$3.42M 10-Q · filed 2024-11-06 | -$6.52M derived: sum of 2 quarters · filed 2024-11-06 | -$9.25M 10-Q · filed 2024-11-06 | -$12.36M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$3.10M 10-Q · filed 2024-11-06 | -$5.83M 10-Q · filed 2024-08-12 | -$8.94M derived: sum of 3 quarters · filed 2024-11-06 | -$12.96M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-03-31 | -$2.74M 10-Q · filed 2024-11-06 | -$5.84M derived: sum of 2 quarters · filed 2024-11-06 | -$9.86M derived: sum of 3 quarters · filed 2024-11-06 | -$13.28M derived: sum of 4 quarters · filed 2024-11-06 |
| 2022-12-31 | -$3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$7.13M derived: sum of 2 quarters · filed 2024-03-19 | -$10.54M derived: sum of 3 quarters · filed 2024-03-19 | -$12.24M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$4.02M 10-Q · filed 2023-11-08 | -$7.43M derived: sum of 2 quarters · filed 2023-11-08 | -$9.14M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$3.41M 10-Q · filed 2023-11-08 | -$5.12M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$1.70M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | -$4.89M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |